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ABSTRACT 
 
The ubiquitin proteasome system (UPS) is the main degradation system in the 
eukaryotic cell and it is involved in the regulation of many crucial cellular pathways; such as 
signal transduction, proliferation, DNA repair, cell death, and cell cycle regulation. In 
comparison to cells in healthy tissues, cancer cells proliferate faster and have increased 
protein synthesis rate; therefore in order to preserve cellular fitness they are more dependent 
on UPS than normal cells. This therapeutic window has been investigated for more than 30 
years and intensive studies led to the discovery of first and second generation 20S proteasome 
inhibitors that have been successfully applied in the treatment of multiple myeloma and 
mantle cell lymphoma. However; in spite of initial positive outcomes, patients eventually 
gain resistance and suffer from the disease relapse. Therefore there is a strong interest in the 
development of new drugs targeting the UPS through alternative mechanisms.   
 b-AP15/VLX1570 is a novel inhibitor of proteasome, recently discovered in 
our group, which does not block the activity of 20S catalytic core, but instead it inhibits two 
19S deubiquitinating enzymes, USP14 and UCHL5. It is a small molecule with α,β-
unsaturated carbonyl units  that binds reversibly to cysteine deubiquitinases via Michael 
reaction. Despite reversible binding of the drug, commitment to death induced by b-
AP15/VLX1570 is irreversible, which is due to the rapid uptake of the drug and subsequent 
retention in the cellular compartment. To some extent cellular response to the treatment with 
b-AP15/VLX1570 and bortezomib are similar: it results in the accumulation of 
polyubiquitinated proteins, induction of ER stress and eventually apoptosis and cell death. 
Treatment with b-AP15/VLX1570 however, induces higher level of proteotoxic stress, higher 
level of ROS and more rapid and potent apoptotic response. We found that VLX1570, a b-
AP15 analogue optimized for clinical administration, has strong anti-cancer activity against 
multiple myeloma and acute lymphoblastic leukemia.  In addition we found that the DUB 
inhibitor is active on cells resistant to bortezomib. This findings suggest that VLX1570 is a 
promising candidate drug and is currently investigated in Phase I clinical trials for the 
treatment of multiple myeloma resistant to conventional proteasome inhibitors.  
Application of proteasome inhibitors in the treatment of solid tumors remains 
limited and primary and acquired resistance continues to be a concern during the 
development of new therapies. Using multicellular spheroids as solid tumor model, we 
discovered that overexpression of PA28, a stress-induced regulatory particle of proteasome, 
can moderate the response of cancer cells to proteasome inhibitors.  
 Taken together our data shows that proteasome DUB inhibitors have potential 
as a treatment option for malignancies and that differences in UPS expression may have 
relevance for the survival of different tumor types. 
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1. INTRODUCTION 
1.1. CANCER AND CANCER TREATMENT 
Cancer remains one of the major causes of death worldwide. According to the World Health 
Organization report from 2012 there were 14,1 million new cancer cases and 8,2 million 
deaths [1]. Despite the improvements in the field of oncology, it is expected that in the next 
ten years the number of diagnosed cases will rise to 20 million annually [2]. Increasing 
progress in early diagnostic methods and rapid development of new therapeutics have helped 
to decrease the mortality rate for many tumor types. In developed countries however, a 
transition can be observed from infection-related cancers to diseases associated with lifestyle, 
hormonal and dietary factors [2]. In fact around 90% of tumors are correlated to 
environmental factors and only the remaining 10% are due to inherited mutations [3]. 
Therefore a better knowledge and understanding of the mechanisms behind tumor initiation 
and progression is essential for prevention and development of new treatments. 
Cancer is an extremely heterogeneous disease; under the single term one can distinguish 120 
different types of malignancies. Traditional classification of tumors is based on histological 
features and the site of origin. The major drawback of this classification is that it does not 
account for molecular differences between cells. Tumors that share similar morphology often 
do not respond identically to treatment and give different clinical outcomes [4],[5]. Therefore 
modern classification of tumors attempts to combine histopathology and molecular analysis 
in order to identify the specific type of malignancy and apply appropriate treatment.  Despite 
the heterogeneity there are several features unique for cancer cells; genetic instability, 
immortality, continuous proliferation, evasion from growth suppression, resistance to induced 
cell death, active angiogenesis, invasion and metastasis, deregulated cell metabolism, escape 
form immune system surveillance and prolonged inflammation [6],[7]. This set of unique 
characteristics enables cancer cell to survive, proliferate in uncontrolled manner and 
eventually metastasize.  
Additional level of complexity is added by the tumor microenvironment. Constant cross talk 
between tumor microenvironment components and malignant cells enables them to adapt to 
hostile conditions and thrive [8]. Vascular cells, fibroblasts, immune cells, and extracellular 
matrix associated with tumors create an environment suited for tumor progression [9]. In 
addition abnormal vasculature of tumors results in disrupted balance of factors such as cell 
metabolites, available nutrients, oxygen level and local pH of the microenvironment. These 
changed biochemical conditions have been proposed to modulate tumor cell metabolism and 
promote tumor survival [10],[11]. Tumor microenvironment not only affects development of 
the disease but also affects the delivery of the drug and limits response to treatment; therefore 
several treatment regimens attempt to target the microenvironment alongside with cancer 
cells [12],[13] . 
Treatment of cancer has remained a challenge for many decades. Despite the major advances 
in the field of cancer therapy, the early-developed treatment lines such as surgery and 
radiation are still broadly used. Surgical removal of a primary tumor is in many cases, a 
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sufficient and minimally invasive approach that has been successfully applied for treatment 
of many solid tumors such as lung, breast or colorectal cancer [14].  
Another well established localized treatment is radiotherapy, which is applied to 
approximately 50% of diagnosed patients [15]. Under the principal of radiotherapy lies the 
fact that many tumor cells have impaired deoxyribonucleic acid (DNA) repair systems and 
therefore are more sensitive to DNA damage than normal cells [16].  Exposure of the cells to 
optimized does of high-energy radiation results in DNA damage and consequently inhibition 
of cell growth and proliferation. Radiotherapy can be successfully used as a single therapy 
agent for treatment of cancers such as head and neck carcinomas, prostate carcinomas or non-
small cell lung carcinomas. On the other hand some cancer types are particularly radio-
resistant such as melanomas or glioblastomas [15]. In addition in many cases localization of 
the tumor is not favorable and/or malignancy is diagnosed at the metastatic stage of disease 
progression, therefore systemic treatment strategies need to be applied.   
Chemotherapy is a conventional treatment approach in which cytotoxic agents are exploited.  
Several classes of chemotherapeutics can be distinguished such as alkylating agents, anti-
metabolites, antibiotics, topoisomerase inhibitors and microtubule stabilizers [17]. Typically 
these agents block cell proliferation by interfering with cell cycle components or by direct 
intercalation with DNA. This activity is not tumor specific and the effect on non-cancerous 
tissues can lead to severe side effects. The efficacy of the therapy relies on the features of the 
tumor cell such as high proliferation rate, dependency on functional repair systems and the 
need for continues supply of cellular building blocks [18].  
Intensified studies of tumor cell phenotypes/genotypes led to identification of alterations in 
growth and proliferation pathways and eventually resulted in development of targeted therapy 
[19]. Targeted therapies aim to directly attack the ‘hallmarks of cancer’, therefore induce cell 
death specifically in tumor cells. Some features that allow cancer cell to thrive such as 
oncogene addiction, increased mutation and DNA damage rate, metabolic reprogramming, 
elevated proteotoxic and oxidative stress and cancer-stroma cross talk has been exploited for 
successful development of therapies. Diverse range of molecules such as signal transduction 
inhibitors, gene expression modulators, apoptosis inducers or angiogenesis inhibitors are 
clinically used [20].   
The discovery of immunosurveilance and the ability of the host immune system to recognize 
and destroy malignant cells resulted in growing interest in cancer immunotherapy [21].  Two 
strategies are investigated: active and passive immunotherapy [22]. Passive immunotherapy 
relies on application of external immunogenic factors such as; tumor targeting monoclonal 
antibodies, which specifically bind and neutralize antigens expressed on cancer cells or 
patient-derived cells of immune system (tumor infiltrating lymphocytes or T-cells), that have 
been genetically modified to increase killing efficiency. Active immunotherapy is focused on 
boosting the existing immune response of the host by immunogenic cell death inducers. 
Many traditionally used chemotherapeutics elicit immunomodulatory effects especially when 
combined with other forms of immunotherapy.  Cancer cell death induced by oncolytic virus 
infection concurrently leads to massive release of tumor-associated antigens attracting cells of 
the immune system. In addition immune system can be stimulated directly by anticancer 
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vaccines, immunostymulatory cytokines or immunmodulatory mAbs or indirectly by 
inhibitors of immunosuppression [22]. 
Despite the vast array of therapy strategies, the field of oncology is constantly struggling with 
resistance and remission of the disease. Cancer cells are highly dynamic and eventually 
acquire sets of resistance mechanisms such as mutations in drug targets, circumvention of 
inhibited pathway, overexpression of drug exporters, mutations in cell death pathways, 
reprogramming of tumor cell metabolism or escaping immunosurveillance [19]. Therefore, 
treatment of a complex and diverse disease such as cancer demands a systemic approach, 
integrating knowledge from many fields and ideally combining several lines of treatment 
[23],[24].  
1.2. CELLULAR DEGRADATION PATHWAYS 
Cancer is a dynamic disease of disrupted cellular balance. Proteins are essential building and 
functional blocks of living cells; therefore protein levels must remain under continuous 
control in order to maintain cellular homeostasis. Cellular needs for proteins are fulfilled by 
the tightly synchronized action of protein synthesis and the rate of destruction [25]. In 
eukaryotic cells there are two main pathways for protein degradation: lysosomal-mediated 
proteolysis and the ubiquitin-proteasome system (UPS) [26],[27]. In 2004 Aaron 
Ciechanover, Avram Hershko and Irwin Rose were awarded with the Nobel Prize in 
Chemistry for studies on Ub-mediated protein degradation and in 2016 Yoshinori Ohsumi 
was awarded with the Nobel Prize in Medicine for discovery of autophagy mechanism. 
1.2.1. Ubiquitin proteasome system 
Since the discovery of the UPS it has been shown that more than 80% of cellular proteins are 
targeted to this molecular shredding system, particularly short-lived proteins, including cell 
cycle regulators, transcription factors, DNA damage repair proteins, cell signaling molecules, 
oncogenes and tumor suppressors [27],[28]. In addition proteasomes are also involved in 
recognition and clearance of damaged and misfolded proteins from the cell. Many 
polypeptides from processed proteins are presented on major histocompatibility complex 
(MHC) class I, suggesting an important role of proteasome in immunesurveilane.  
Considering the diverse role of UPS function it is not a surprise that alterations in UPS 
pathway are correlated with many human diseases such as neurodegenerative disorders or 
cancer [29]. The process of UPS mediated protein degradation can be divided into two main 
steps; tagging the target by ubiquitination and subsequent proteolysis in proteasome 
(Figure1). 
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Figure 1. Structure and function of ubiquitin-proteasome system 
Ubiquitination  
 In the first step of proteasome degradation a target protein is labeled with ubiquitin, a small, 
(76 amino acids) and highly protein. Ubiquitin conjugation is performed by the coordinated 
action of three classes of enzymes: an ubiquitin-activating enzyme (E1); ubiquitin-
conjugating enzyme (E2) and an ubiquitin-ligating enzyme (E3).  E1 activates ubiquitin via 
association of the carboxy-terminal glycine residue of ubiquitin and the active site cysteine of 
the E1 enzyme in the presence of ATP. Activated ubiquitin can be transferred to a cysteine 
residue of an E2 enzyme that is further recruited by a substrate specific E3 ligase, which 
coordinates the attachment of an ubiquitin moiety to lysine residues in target proteins [30]. 
Proteins can be modified with a single ubiquitin molecule conjugated to one or several lysine 
residues or with a multi-ubiquitin chain. Mono-ubiquitination is involved in histone 
modification, endocytosis, protein trafficking and intracellular localization and DNA damage 
repair [31],[32]. Self-conjugation of the ubiquitin moiety can occur at any of the seven 
internal lysine residues  (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63).  The type of 
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linkages within a polyubiquitin chain determines the fate of a modified protein. In the 
canonical model, proteins tagged with four or more Lys48-linked ubiquitin subunits are 
considered as proteasome substrates [33]. Other modifications remain less characterized, 
however recent studies show that unconventional polyubiquitin chains linked through Lys6, 
Lys11, Lys27, Lys29 and Lys33 are abundant in vivo and may target specific substrates to the 
UPS [34]. Additionally it has been reported that Lys63-modification, typically associated 
with non-proteasomal functions such as protein sorting, DNA damage repair, kinase signal 
transduction and receptor endocytosis, can also serve as a proteasome-targeting signal 
[35],[36]. In human cell there are approximately 30 types of E2 enzymes, and 500-1000 E3 
ligases, which allows for thousands of E2-E3 combinations and possible forms of substrate 
modification. Therefore it is not surprising that ubiquitinataion is emerging as one of key 
regulators of protein homeostasis [32]. 
Ubiquitination is opposed by the activity of deubiquitinases (DUBs, ubiquitin isopeptidases). 
DUB enzymes disassemble ubiquitin chains and remove them from target proteins by 
hydrolyzing the isopeptide bond between the lysine residue on target proteins and the C-
terminal glycine on ubiquitin [37]. There are six different classes of DUBs: ubiquitin-specific 
proteases (USPs), ubiquitin carboxy-terminal hydrolases (UCHs), ovarian-tumor proteases 
(OTUs), Machado–Joseph disease protein domain proteases (MJDs or Josephins), 
JAMM/MPN domain-associated metallopeptidases (JAMMs) and monocyte chemotactic 
protein-induced proteases (MCPIP) [38]. There are about 100 DUBs in human cells, where 
the USPs are the most numerous, followed by the OTUs, JAMMs, UCHs and Josephins. The 
distinct linkages between ubiquitin molecules result in different chain conformations, serving 
as a pattern for recognition by various DUBs. Some DUBs show specificity for only one type 
of chain, whereas others do not discriminate between chain types [39]. DUBs can preferably 
cleave in the middle (endo-) or from the end (exo-) of an ubiquitin chain, which results in 
chain trimming or removal of monoubiquitination, respectively. DUBs and E3 ligase 
diversification partially explains the key role of the UPS in a multiple and various regulatory 
circuits.  
Proteasome structure and function 
Ubiquitinated substrates are hydrolyzed into small peptides by a molecular shredder called 
the 26S proteasome. The 26S proteasome is a large (2,5 MDa) multimeric complex, that can 
be furtherly devided into 20S core particle (CP) and 19S regulatory particle (19S RP).  The 
eukaryotic 20S CP is a 730 kDa barrel-shaped structure with a central cavity, formed by axial 
stacking of four heteroheptameric rings. The two inner rings are composed of seven β-
subunits and the two outer rings are composed of seven α-subunits giving together the 
general structure of the complex α1-7β1-7β1-7α1-7 [40],[41]. β3, β4, β6 and β7 subunits have 
mainly structural function, whereas β1, β2 and β5 carry the caspase like/PGPH 
(peptidylglutamyl-peptide hydrolyzing), trypsin-like and chemotrypsin-like activities, 
respectively. This diversity in peptidase activity confers the proteasome with proteolytic 
activity and allows for cleavage of acidic, basic and hydrophobic amino-acid residues, 
respectively. Catalytically active threonine residues at the N-termini of proteolytic subunits 
protrude into the center of the 20S chamber where substrate proteins are hydrolyzed 
[42],[43]. Produced oligopeptides range in the length from 3 to 15 amino acids and can be 
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further degraded by cellular proteases, feeding the amino acid pool of the cell. If not digested 
they can serve as antigens, presented to the immune system by the MHC class I [44]. In order 
to reach the catalytic chamber formed by β-rings, substrate proteins need to pass through a 
narrow (13 Å in diameter) channel created by α-rings.  Crossing the passage is preceded by 
recognition of polyubiquitinated substrate, removal of ubiquitin chain and unwinding of 
substrate protein tertiary structure, all of this performed at the 19S RP [43].  
The 19S RP is a 930 kDa complex, composed of lid and base structures. The lid contains 9 
non-ATPase subunits Rpn3, Rpn5-9, Rpn11, Rpn12 and Rpn15 and the base contains 10 
subunits, six of which are related AAA+ ATPases that form a heterohexameric ring [45],[46]. 
The ATPase ring utilizes the energy from ATP hydrolysis to unwind the tertiary and 
secondary structure of a substrate and to translocate it into the narrow 20S catalytic core [47]. 
The Rpn1 and Rpn2 subunits of the 19S base serve as binding sites for deubiquitinases 
(Ubp6/USP14) and E3 ligases (Hul5) indicating that ubiquitination is a highly dynamic 
process and that substrate fate can be changed even upon binding to the proteasome [48]. 
Substrate recognition is performed by the ubiquitin receptors Rpn10 and Rpn13 that bind 
Lys48 linked polyubiquitin chains with high affinity [49]. Three extrinsic ubiquitin receptors 
(Rad23, Dsk2, Ddi1) can also modulate the binding preference towards specific ubiquitin 
linkages and chain lengths. In addition Rpn13 also serves as a binding site for the DUB 
Uch37/UCHL5, providing a crosstalk site between chain recognition and disassembly [49]–
[52].  
Bulky ubiquitin chains interfere with the translocation of substrates into the proteasome; 
therefore deubiquitination is a crucial step for efficient proteolysis. In addition, DUBs clear 
the proteasome from substrate-free ubiquitin chains, leaving receptors available for the next 
interaction. Deubiquitination participates in maintaining an adequate level of ubiquitin 
molecules, which is essential for cell viability and the cells ability to withstand stress. 
Ubiquitin homeostasis is regulated by DUB activity, synthesis rate and proteasomal 
proteolysis, where ubiquitin can be degraded as a free monomer or as remnants attached to a 
targeted protein [52]. Finally deubiquitination can result in rescue of weakly ubiquitinated 
substrates by trimming the poly-ubiquitin chain from the distal end [53]. 
19S deubiquitinating enzymes 
There are three DUB enzymes associated with the proteasome Rpn11/POH1, Ubp6/USP14 
and Uch37/UCHl5 (yeast/human nomenclature), metalloprotease JAMM, USP and UCH 
family, respectively [50]. Rpn11/POH1 is a constituent part of the 19S lid, essential for cell 
viability, as well as 26S proteasome structure and activity [54],[55]. It is located above the 
entrance of the ATPase ring and makes extensive contact with Rpt3 in the base and Rpn8, 
Rpn9 and Rpn5 in the lid [46]. Positioning of the enzyme and the fact that Rpn11/POH1-
mediated deubiquitination requires hydrolysis of ATP, indicates that the process is tightly 
linked to protein unfolding and substrate translocation into the 20S core. Rpn11/POH1-
mediated deubiquitination is thought to promote substrate degradation [56],[57]. 
Concurrently Rpn11/POH1 activity is delayed until the substrate is committed to degradation. 
To span the distance between Rpn10 or Rpn13 ubiquitin receptors and Rpn11/POH1 the 
polyubiquitin chain must contain at least four ubiquitin moieties. Trimming the chain prior to 
degradation commitment by the two residual 19S DUBs, decreases substrate binding affinity 
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and promotes its dissociation from the proteasome [58]. Preferable substrates for 
Rpn11/POH1 are ubiquitin chains linked by Lys63 [59]. Ubp6/USP14 and Uch37/UCHL5 
are cysteine proteases and unlike Rpn11/POH1, are non-essential for proteasome integrity. 
They associate with proteasome via Rpn1 and Rpn13 subunits, respectively. The active sites 
of these enzymes are inhibited by crossover loops and upon binding to the proteasome 
conformational changes expose the ubiquitin-binding site and allow for deubiquitination 
[60],[61]. In comparison to Rpn11/POH1, Ubp6/USP14 and Uch37/UCHL5 are located at a 
larger distance from the 20S entrance pore, therefore they presumably clip extended ubiquitin 
chains from the distal tip or within a chain. Ubp6/USP14 releases di and tri-ubiquitin whereas 
Uch37/UCHl5 cleaves off single ubiquitin moieties [60],[62]. Ubp6/USP14 cleaves 
preferably Lys48-linked chains, whereas Uch37/UCHL5 can cleave  both Lys48- and Lys63- 
linked chains [63]. Proteasome associated DUBs cooperate to provide effective and 
controlled processing of ubiquitin chains and thus ubiquitin-tagged substrates. A mechanism 
proposed for this cooperation suggests that USP14/UCHL5 mediated deubiqutination 
prevents deubiquitination by Rpn11/POH1 and therefore delays protein degradation by 
proteasome [58],[64]. Additionally, Ubp6/USP14 regulates opening of the 20S gate and 
therefore integrates the step of substrate binding and proteolysis [65]. Single knock-down of 
Rpn11/POH1 or double knockdown of Ubp6/USP14 and Uch37/UCHL5 leads to a similar 
phenotype with inhibition of cell growth, decreased rate of protein degradation and 
accumulation of polyubiquitin chains [55]. Surprisingly Koulich et al. show that RNAi-
mediated down-regulation of either DUB alone does not affect cell growth and it increases 
the rate of proteasome activity, suggesting that these enzymes may have redundant roles [53]. 
The detailed mechanisms of the degree of cooperation between DUBs are yet to be 
discovered. 
1.2.2. Autophagy 
Autophagy is a lysosome dependent degradation pathway of many cytoplasmic components, 
especially long-lived proteins and organelles. An assembly of a unique organelle called 
autophagosome characterizes the process [66]. The double membrane vesicle engulfs a 
portion of the cytoplasm and after subsequent fusion with the lysosome, mediates degradation 
of the cargo. Autophagy can be divided into several steps: induction, vesicle formation, 
vesicle maturation and degradation. Induction of autophagy is coordinated by sensors of 
cellular energy level, 5’ adenosine monophosphate-activated protein kinase (AMPK) and 
mechanistic targets of rapamycin complex 1 (mTORC1), autophagy inducer and inhibitor, 
respectively [67]. During phagophore formation and elongation a set of autophagy related 
(ATG) proteins is recruited. Coordinated action of ATG proteins results in generation of 
3,4,5-triphosphate (PI3P) on membranes destined to become a phagophore and mediates 
elongation of the membranes until the vesicle closes and forms an autophagosome [68]. 
Maturation phase requires special ATG8 protein – microtubule-associated prptein1A/1B-
ligth chain 3 (LC3). Formation of phosphatidylethanolamine-lipidated LC3 (LC3-II) and 
incorporation into phagosome membrane is coordinated by ubiquitin-like conjugation 
system [69].  
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Autophagy is executed with a different type of specificity; unselective autophagy, during 
which big portions of cytoplasm are processed for nutrient recycling or selective autophagy, 
when specific cargo is targeted for degradation [70]. In a living cell a basal level of 
autophagy is maintained for clearance of non-functional proteins or organelles, in order to 
preserve cellular homeostasis and provide continuous supply of nutrients and building blocks 
[71]. Interaction between membrane-bound LC3, which serves as a cargo receptor and an 
adaptor protein, such as sequestome 1 (p62/SQSTM1), enables recognition and 
sequestration of specific substrates [72]. Additional level of inducible autophagy is triggered 
by stress conditions such as; starvation, hypoxia or oxidative stress [73]. Nonselective 
engulfment of cytoplasmic material is typical for induced autophagy. The level of 
autophagy often decides on cell fate and extensive autophagic processes can lead to apoptosis 
[74]. 
Autophagy plays a dual role in cancer and depending on the context can be tumor inhibiting 
or tumor promoting [75]. Signaling pathways that regulate tumor growth and autophagy have   
common nodes of interaction. Activation of the PI3K-AKT-mTOR pathway, a common 
event in many cancers, inhibits autophagy [76]. Mutations and deletions of several ATG 
genes have been identified in prostate, breasts, ovarian and colon cancers. Finally, mouse 
models with deficient autophagy develop multiple tumors [75]. As described before, basal 
autophagy protects cells from metabolic and oxidative stress, however; deregulation of 
autophagy can result in ROS production, accumulation of cellular waste and genomic 
instability, common factors promoting malignant transformation [77]. On the other hand in 
already formed tumors, autophagy helps to preserve the fitness of malignant cells in a hostile 
environment. Metabolic changes of cancer cells count for elevated autophagy to reduce 
stress, recycle nutrients and allow cells to survive. In addition autophagy has been proposed 
as a resistant mechanism to many types of drugs, whose activity relies on stress induction 
above tolerance threshold of cancer cell. Therefore blocking autophagy is considered as a 
beneficial strategy for increasing the efficacy of radio- and chemotherapy [78].  
1.2.3. UPS-Autophagy crosstalk 
The two cellular degradation pathways were initially considered as distinct and unrelated, 
however there is rising evidence for an extensive crosstalk between and cooperation between 
them (Figure 2) [79]–[81]. As described in previous chapters UPS-based degradation is 
believed to be more precise and focused on degradation of soluble and short-lived proteins 
[28]; whereas it is suggested that autophagy is a less specific mechanism for degradation of 
long-lived proteins, bulky misfolded proteins, insoluble protein aggregates or whole 
organelles [66]. It is also speculated that with age autophagy is favorable over UPS [82]. 
Common denominator between these two mechanisms is the ubiquitin molecule and several 
adaptor molecules [83]. Autophagy is a cell contingency plan when proteasome is overloaded 
for example in situation of extensive ER stress or accumulation of protein aggregates 
[84],[85].  It is also a form of rescue after proteasome inhibition [86]. Finally 26S proteasome 
itself was found to be degraded by autophagy [87]. 
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Figure 2. Crosstalk between ubiquitin-proteasome system and autophagy 
1.3. UPS FUNCTION IN CANCER DEVELOPMENT 
The UPS is involved in the regulation of many crucial cellular pathways; such as signal 
transduction, proliferation, DNA repair, cell death, and cell cycle regulation [88]. Balance 
between action of E3 ligases, and deubiquitinating enzymes (both cytosolic and proteasome-
bound) allow for precise control of signaling molecules and their receptors. Finally UPS 
protects cells from toxic and damaged proteins. Taking all this function together, it is not a 
surprise that deregulation of the system underlies the pathogenesis of many human diseases 
such as Parkinson disease or cancer [89],[90].  
In order to proliferate in uncontrolled manner cancer cells escape from cell cycle chekpoints, 
and ubiquitination and deubiquitination events have been proven to be essential for cell cycle 
regulation [91]. Cell cycle is regulated by periodic activation cyclin dependent kinases 
(CDKs) and it’s key regulators: cyclins (D, E, A, B) and CDKs inhibitors (p21Cip1 and 
p27Kip1). Sufficient level of these key regulators is in turn maintained by the ubiquitin-
mediated proteolysis and aberrations in the process are found in many types of cancers. There 
are two main E3 ubiquitin ligases involved: the SKP1–Cullin1–F-box-protein (SCF) complex 
and the anaphase-promoting complex/cyclosome (APC/C). Depending on co-regulators 
involved, SCF can act as tumor promoter or suppressor, since it participates in ubiquitination 
of cell cycle inhibitors: p21Cip1 and p27Kip1 and cell cycle promoters: cyclinE, c-myc, Notch 
[92]. APC/C is active mainly in anaphase and the beginning of the G1 phase, whereas the 
SCF complex is active from late G1 to the initiation of M phase. USP44 is a key regulator of 
APC activity, preventing its premature activation. USP44 is suggested to function as tumor 
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suppressor and cells with down regulated USP44 are prone to chromosome segregation errors 
[88],[93]. USP2a cleaves ubiquitin from cyclin D and cyclin A1; leading to increased protein 
levels and enhancement of cell proliferation in cancer cells [94],[95]. USP19 activity supports 
cell proliferation by promoting p27Kip1 degradation [96]. USP28 was also demonstrated to act 
as tumor promoter by deubiquitinating and stabilizing Myc in colon and breast carcinoma 
cells [97].  
P53 is an important tumor suppressor and regulator of cell proliferation, apoptosis, 
senescence and cell growth. In response to DNA damage or oncogene signaling p53 induces 
genes responsible for growth arrest and apoptosis. It is commonly mutated in many types of 
cancer [98]. Ubiquitination has been proposed as the main regulatory mechanism of p53 
level, which is normally maintained low via the interaction with its negative regulator Mdm2 
[99]. Mdm2 is an E3 ubiquitin ligase, that ubiquitinates both p53 and itself. The DUB 
HAUSP/USP7 has a dual role in p53 stabilization. Direct deubiquitination stabilizes p53, 
however HAUSP/USP7 activity also stabilizes Mdm2, creating a negative loop for p53 
signaling [100]. To add an additional level of complexity, USP2a has been identified as a 
regulator of the Mdm2/p53 pathway. USP2a binds and deubiquitinates Mdm2/MdmX and 
indirectly stabilizes p53 [101]. Many additional DUBs have been implicated in p53 
regulation. USP10 determines p53 localization after DNA damage, when phosphorylated 
USP10 is translocated into the nucleus, where it deubiquitinates p53 and prevents its nuclear 
export and degradation [102]. USP22 inhibits p53 transcriptional activation by 
deubiquitinating the class III histone deacetylase Sirt-1 and H2A and H2B histones 
[103],[104]. Finally USP42 directly interacts with p53 and controls its ubiquitination level 
during stress responses [105].  
Cancer cells have the ability to evade programmed cell death by increasing the ratio between 
anti-apoptotic and pro-apoptotic proteins. Many proteins directly involved in the apoptotic 
response belong to the Bcl-2 family [106]. Pro-apoptotic Bcl-2 family members (Bax, Bad, 
Bid) trigger release of cytocochrom c from mitochondria, which in turn activates caspase 
cascade and apoptosis. On the other hand anti-apoptotic proteins such as Bcl-2, Bcl-XL and 
Mcl-1 promote cell survival. The balance between pro-apoptotic and anti-apoptotic proteins 
is maintained by UPS degradation [107]. Four different E3 ligases and USP9x deubiquitinase 
have been shown to regulate pro-survival Mcl-1 [108]. Mcl-1 overexpression has been 
correlated with poor prognosis in lymphocytic leukemia, multiple myeloma and breast cancer 
[109]. Uchl37/UCHL5 promotes expression of anti apoptotic Bcl-2 and UCHL5 knockout 
results in elevated level of pro-apoptotic Bax in a lung adenocarcinoma epithelial cell line 
[110]. Bax is under regulation of the IBRDC2 ligase and increased proteasomal degradation 
of Bax is associated with poor prognosis in chronic lymphocytic leukemia [111]. At certain 
threshold of induced apoptosis, IAPs (inhibitor of apoptosis) bind to caspases and sequester 
apoptotic signaling [112]. IAPs stability is regulated by USP19 [113] and in addition IAPs 
themselves carry an E3 ligase domain and can inactivate caspase via direct ubiquitination 
[114]. 
Nuclear factor kappa B (NFκB) is a transcription factor with a well-established role in 
promoting cancer due to its anti-apoptotic and pro- inflammatory functions [115]. The DUB 
CYLD has been suggested as an important tumor suppressor, since it can promote apoptosis 
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by increasing the stability of IκB, the endogenous inhibitor of NFκB [116]. On the other 
hand, overexpression of the 19S DUB USP14 was shown to reduce IκB levels in lung 
epithelial cells [117]. NFκB signaling is also down-regulated by the E3 ligase domain of the 
A20 protein [118]. Interestingly several studies show that NFκB can up-regulate pro-
apoptotic genes such as Bax or p53 and therefore act rather as a tumor suppressor than tumor 
promoter [120],[121]. Another well-established mediator of apoptosis and stress related 
response is c-Jun-N-terminal Kinase (JNK) that belongs to mitogen-activated protein kinases 
(MAPK) family. JNK is activated by the AP1 (activator protein 1) transcription factor, c-Jun, 
which is regulated by Rpn11/POH1 [121]. 
Transforming growth factor-β (TGF-β) signaling is yet another signaling cascade commonly 
altered in human cancers [122]. Smads are mediators of TGF-β signaling and Smad4 
monoubiquitination antagonizes its activity. USP9x has been shown to deubiquitinate Smad4 
and restore TGF-β signaling [123]. TGF-β signaling is attenuated by inhibitory Smads that 
recruit the E3 ligase Smurf to the TGF-β receptor and promote its degradation. USP11 and 
Uch37/UCHL5 have been found to rescue the receptor from proteasomal degradation and 
promote cell migration and metastatic potential mediated via TGF-β signaling [124]–[126]. 
DNA repair pathways are often defective in cancer resulting in a mutator phenotype. 
POH1/Rpn11, USP11 and BRCC36 activity was suggested to regulate BRCA1- mediated 
DNA repair [127],[128] and USP28 was shown to regulate the Chk2–p53–PUMA-signaling 
pathway, important for DNA-damage-induced apoptosis [129]. 
Finally, activity of receptor tyrosine kinases (RTKs) is associated with many tumor types. 
One way of terminating the proliferative signal is receptor ubiquitination, which serves as a 
signal for receptor internalization and endosomal packing [130]. AMSH and USP8 are two 
well-established DUBs that participate in the down regulation of the epidermal growth factor 
receptor (EGFR) through the described mechanism [131],[132]. Depletion of either USP8 or 
AMSH results in deregulation of stimulated EGFR levels in several cancer types. Similarly 
POH1 has been shown to regulate the expression of HER2, another oncogenic RTK. 
Deubiquitination by POH1 rescues HER2 from proteasomal degradation and stimulates its 
recycling to the cell surface [133]. USP9x interacts with and stabilizes β-catenin, a member 
of the Wnt signaling pathway involved in the pathogenesis of colon cancer [134],[135]. A 
similar function was discovered for USP14 and correlated with overall survival of lung 
carcincoma patients [136]. 
1.4. TARGETING UPS IN CANCER TREATMENT 
Pervasiveness of ubiquitin signaling makes it a very attractive target for therapeutic research 
[137]. Blocking the UPS at different nodes can be used to eliminate cancer cells via cell cycle 
arrest, elevated apoptosis and increased proteotoxic stress [138]. UPS can be targeted at the 
level of E1, E2, E3 enzymes, deubiquitinases and proteasome [139]. There are several 
attempts to develop E1 or E2 inhibitors, however this enzymes have very broad spectrum of 
action and inhibition may result in multiple side effects [139],[140]. E3 is the most specific 
class of enzyme in UPS system and several compounds interfering with p53 or p27Kip1 
ubiquitination are under investigation. DUB enzymes are also potentially drugable targets, 
however as they are cysteine kinases, abundant in cellular cytoplasm, specificity of developed 
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drugs is questionable. As previously described 19S DUBs undergo conformational change 
upon binding to proteasome and therefore are potentially better targets [60],[61]. Most of 
today clinically used or tested drugs are proteasome inhibitors [141]. Cytotoxicity of 
proteasome inhibitors is mediated by inhibition of cell cycle, induction of pro-apoptotic 
signaling, ER stress and oxidative stress [142]. 
 
 
Figure 3. Effects of proteasome inhibition  
1.4.1. Cell cycle inhibition and apoptosis 
Levels of proteins involved in cell cycle are tightly control by UPS and inhibition of 
proteasome results in stabilization of negative cell cycle regulators and pro-apoptotic 
proteins. Accumulation of p27Kip1 and p21Cip1 results in cell cycle arrest in G2/M phase [143]. 
Prolonged cell cycle arrest triggers apoptosis, probably due to accumulation of p53 and 
p53induced pro-apoptotic genes, such as Bax [144]. Some evidence however, show that 
proteasome inhibitors can induce apoptosis independently from p53 expression [145],[146]. 
Furthermore, although anti-apoptotic members of Bcl-2 family are also proteasome 
substrates, apparently accumulation of protective signal is not able to protect cells from 
induced cell death [146],[111]. Pro-survival NFκB is bound and inhibited in the cytoplasm by 
IκB, a proteasome substrate. Accumulation of IκB after the proteasome inhibition prevents 
maturation of NFκB, transport of active subunits to the nucleus and induces apoptosis [147]. 
On the other hand, some studies show that importance of NFκB inhibition is controversial 
and it is not sufficient to induce cell death [148],[149].  
1.4.2. UPR and ER STRESS 
Chaperones such as Hsp70 (Heat shock protein 70) assist folding of newly synthetized or 
misfolded proteins into their native and functional form [150]. A crosstalk between 
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chaperone-mediated repair and degradation is essential for protein quality control and for 
keeping cells free from proteotoxic stress. If the protein damage is too extensive and repair is 
not feasible it is targeted to degradation Chaperones and assisting co-chaperones, decide on 
the type of engaged E2-E3 ligases complex and as a consequence on ubiquitination pattern 
and protein fate. K-48-linked chains target the substrate to the proteasome, while Lys29-, 
Lys63- linked chaines or monoubiquitination are preferable for autophagy-mediated 
degradation [151],[152]. CHIP (C-terminus of Hsp70- interacting protein) and BAG (Bcl-2-
associated athanogene) are co-chaperone molecules able to switch the fate of candidate 
proteins between two forms of degradation [82],[153]. CHIP is a co-chaperone of Hsp70 and 
Hsp90 and concurrently an E3 ubiquitin ligase [153],[154]. Via its functional domains it can 
ubiquitinate Hsp70 substrate, interact with the proteasome or autophagosome and actively 
switch between these two systems. In addition, BAG1 interacts with both CHIP and the 
proteasome and mediates recruitment of Hsp70 to the proteasome [155],[156]. On the other 
hand BAG3 preferentially targets for autophagy-mediated degradation and therefore 
BAG1/BAG3 ratio defines predominant degradation system.  
Newly synthetized proteins undergo chaperone-mediated folding and postranslational 
modifications in endoplasmic reticulum (ER) to gain their functional structure, however 
mutations in protein coding genes or ER dysfunction can lead to misfolding. Such damaged 
proteins are transported from ER to proteasome in a process called ER-associated degradation 
(ERAD) [157]. P97/VCP (valosin-containing protein) chaperone is a AAA+ ATPase that is 
necessary for transportation of proteins from ER to the proteasome [158]. In case of ER stress 
or proteasome overload, global protein synthesis rate is down regulated, but a specific set of 
genes involved in the unfolded protein response (UPR) is up regulated: activating 
transcription-factor 6 (ATF6), inositol- requiring enzyme 1α (IRE1α) and protein kinase 
RNA-like kinase (PERK). If ERAD fails to clean ER from accumulated damaged proteins, 
ER-activated autophagy (ERAA) is triggered [159]. ATF6 increases expression of ER 
associated chaperones such as Bip/Grp78, an ER homologue of Hsp70 [160]. Upon 
activation, PERK phosphorylates and deactivates translation initiation factor eIF2α, therefore 
indirectly inhibits mRNA translation and reduces the flux of new proteins to ER. 
Simultaneously translation of ATF4 (activating transcription factor 4) and its target genes: 
transcription factor CHOP (C/EBP homologous protein) and GADD34 (growth arrest and 
DNA damage–inducible gene 34) is induced. CHOP controls genes involved in apoptotic 
pathway while GADD34 is a negative regulator of PERK activity [160]. PERK/eIF2α 
phosphorylation is also necessary for transformation of LC3 into membrane-bound LC3-II 
form and formation of mature autolysosomes [161]. IRE1α transmembrane 
kinase/endoribonuclease, splices and activates XBP1 (X-box binding protein 1) transcription 
factor, which in turn activates components of ER-mediated degradation path [160]. IRE1 
kinase activity and IRE1-mediated phosphorylation of JNK and Bcl-2 is essential for 
autophagy and apoptosis induced by proteasome inhibitors [84],[162]. Pro-apoptotic ER 
residents (Bax and Bad), regulate level of Ca2+ released from membrane into cytoplasm and 
therefore control Ca2+induced apoptosis [163]. Prolonged UPR induces apoptosis and cell 
death, however for certain types of cancer, especially the ones derived from secretory cells, 
such as multiple myeloma, it can have a protective function [164]. 
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1.4.3. Accumulation of ROS  
Reactive oxygen species (ROS) such as hydrogen peroxide, superoxide radicals, hydroxyl 
radicals, are reminders from cellular oxygen metabolism and they are constantly produced 
in cells utilizing aerobic processes. Leakage from mitochondrial respiratory chain is the 
main generator of ROS, however NAD(P)H oxidase, xanthine oxidase, uncoupled nitric 
oxide synthase and ER stress also contribute to accumulation of free radicals. When the 
level of ROS particles is properly balanced, they can act as signaling molecules in many 
biological processes [165]. Proper levels of ROS are maintained by the activity of various 
antioxidants (Vitamin C and E, gluthathione peroxidase, thioredoxin reductase) [166]. 
When levels of ROS exeedes antioxidant capacity of the cell it can casue damage to cellular 
proteins. If damage is to extensive, oxidaised proteins tend to misfold and form unsoluble 
aggregates. To protect the cell, oxidised proteins can be rapidly degraded in 20S 
proteasome in an ATP and Ub-independent manner [167]. Cancer cells have higher basal 
level of ROS, which was found to be essential for cell proliferation, survival and even 
associated with increased aggressiveness [168]. Some evidence show that elevated ROS may 
even confer resistance to chemotherapy [169]. On the other hand it makes tumor cells more 
vulnerable to disruption of redox homeostasis and it has been exploited in the development of 
new therapeutic strategies [170]. Interestingly, resent study questions correlation between 
level of accumulated ROS and cytotoxicity [171]. Nevertheless, proteasome inhibition leads 
to increased oxidative stress, a process that was found essential for apoptosis induction by 
this compunds. Since treatment with proteasome inhibitors results in a decrease of 
mitochondria membrane pontential, it was concluded that large amount of generated ROS 
upon proteasome inhibiton, comes from depolarization of mitochondirial membranes 
[172],[173]. As described before, p53 regulates level of pro- and anti- apoptotic genes. 
Accumulation of p53 and pro-apoptotic Bcl-2 family proteins affects mitochodrial 
membrane integrity and results in release of  cyrochrome c into the cytoplasm and 
apoptosis [174]. Finally elevated ROS may induce apoptosis through intracellular stress-
sensing kinase cascades such as the MAPK pathway, composed of apoptotic proteins (JNK 
and p38 MAPK) and protective extracellular signal-regulating kinase (ERK) [175]. 
Interestingly proteasome inhibition induces apoptosis through JNK pathway activation 
[176],[177].  
1.4.4. Protein aggregates formation 
Exposure of the cell to stress factors such as heat shock or oxidative stress can result in 
protein unfolding and misfolding. Some of the proteins can neither be successfully repaired 
nor degraded by the proteasome, due to their hydrophobic structure or simply due to their 
abundance and proteasome overload. These proteins tend to form potentially toxic aggregates 
dispersed in cell cytoplasm. To protect the cell from toxicity of insoluble protein clumps, a 
mechanism called aggresome formation is triggered [178]. Aggregates of insoluble proteins 
are transported along a microtubule network to the microtubule organizing center (MTOC). 
One of the key regulators of aggresome formation pathway is microtubule-associated 
deacetylase HDAC6, which recognizes both polyubiquitin chains and the microtubule dynein 
motor, therefore enabling active transport of polyubiquitinated aggregates into the perinuclear 
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area [179]. Another important player is P62/SQSM1, an adaptor protein that has ubiquitin 
and LC3 binding domains and functions as a bridge between autophagosomes and 
polyubiquitinated proteins clustered in aggreseomes [72]. Chaperones, UPS and autophagy 
components are also brought to close proximity in aggresomes in order to participate in 
protein refolding or degradation [180],[181]. On example is P97/VCP chaperone, which 
disrupts interaction between HDAC6 and ubiquitinated proteins and favors proteasomal 
degradation [182]. On the other hand, some reports suggest that aggresome formation may 
inhibit proteasome function and thus favor autophagy-dependent degradation [183]. As 
previously described K63-linked polyubiquitin is a signal for lysosomal degradation and the 
shift between K48 and K63 ubiquitination pattern modulates preferential degradation 
pathway. Aggresome formation is regulated by the interplay between E3 ligases such as 
Parkin and an aggregation-associated DUB Ataxin-3, which determines quantity and length 
of formed K63-linked chains on protein aggregates [184],[185]. Interestingly it was 
suggested that unanchored ubiquitin chains, cleaved off by Ataxin-3, are also recognized by 
HDAC6 [186]. P62/SQSTM1 participates in targeting ubiquitinated proteins into 
autophagosomes, while HDAC6 presence is essential for autophagosome maturation and 
aggresome clearance. It has been shown that under proteasomal stress, lysosomes are 
recruited to MTOC region and HDAC6 triggers F-actin remodeling, which in turn enables 
autophagosome-lysosome fusion and aggrephagy [187],[188]. Furthermore p62/SQSTM1 has 
been found to regulate HDAC6 deacetylase activity and recruitment of F-actin filaments 
[189]. HDAC6 plays an important role in tumorgenesis and tumor progression, protecting 
cells from elevated proteotoxic proteins. Aggresome pathway has been found to be crucial for 
survival of multiple myeloma cells that constantly overproduce proteins. HDAC6 inhibition 
induces apoptosis in multiple myeloma and combination of proteasome HDAC6 inhibitors 
results in the improved treatment outcome [190],[191]. 
1.4.5. Proteasome inhibitors 
Bortezomib (PS-341, NSC 681239, Velcade®; Millennium Pharmaceuticals) was the first 
proteasome inhibitor that gained approval of US Food and Drug Administration (FDA). It is a 
synthetic dipeptide boronic acid and reversible inhibitor of the chymotrypsin-like and 
caspase-like activity of the 20S β5- and β1-subunits [192]. Bortezomib was first introduced 
for treatment of multiple myeloma (MM) and secondly for mantle cell lymphoma 
[193],[194]. Several mechanisms were proposed to explain the selective sensitivity of cell 
lines derived from hematological malignancies to proteasome inhibition. Extensive protein 
synthesis makes MM cells very dependent on proteasomal degradation as a disposal system 
for defective proteins. Accumulation of misfolded protein from the endoplasmic reticulum 
triggers an ER stress response and leads to arrest of protein synthesis [195]. Additionally, the 
high proliferation rate of the malignant cells is dependent on the proper level of cell cycle 
regulators and blocking of proteasomal degradation can lead to cell growth arrest [196]. 
Finally, MM cell lines derived from relapsed patients had elevated levels of pro-survival 
NFκB, therefore negative regulation of NFκB may be advantageous for bortezomib treatment 
[197]. 20S CP inhibition stabilizes the p53 tumor suppressor protein and cyclin kinase 
inhibitors p21Cip1 and p27Kip1 [198],[199]. Increase in the level or pro-apoptotic proteins such 
as Bid, Bax and JNK have also been observed [200],[201]. The role of NFκB pathway is 
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controversial. Some studies suggest that interference with NFκB is essential for bortezomib 
induced cytotoxicity, whereas other shown that inhibition of NFκB signaling may be 
insufficient to induce apoptosis [202], [203]. 
The majority of patients treated with bortezomib suffer from toxic side effects such as 
peripheral neuropathy and thrombocytopenia [204]. Furthermore, patients treated with 
proteasome inhibitors ultimately experience relapse and disease progression. Mechanisms 
underlying resistance development are under investigation. Screening of bortezomib resistant 
cell lines revealed several mutations in PSMB5 gene, encoding the β5 subunit, however these 
were not identified in patients with multiple myeloma [196],[205]. Changes in protetoxicity 
regulators can also confer resistance. Overexpression of the ER chaperone protein Grp78/Bip 
protects mesothelioma cells treated with bortezomib from a typical ER stress response[206]. 
Similarly cells overexpressing heat shock protein 27 (HSP27), involved in control of protein 
folding and defense against oxidative stress, were found to be more resistant [207]. Finally, 
some studies have shown that over-expression of anti-apoptotic Bcl-2 proteins, can block 
bortezomib-induced apoptosis [208],[209] . 
To overcome resistance several strategies for combinational therapy are under investigation. 
Bortezomib was found to act synergistically with DNA-damaging agents like doxorubicin 
and melphalan. Proteasome inhibition can enhance cell sensitivity to chemotherapeutic agents 
due to down regulation of proteins involved in DNA repair [210]. In addition histone 
deacetylase (HDAC) inhibitors were suggested to help in overcoming cytoprotective 
aggresome formation [211]. Inhibition of proteins from antiapoptotic Bcl-2 family can also 
have synergistic effects [212]. In addition a new generation proteasome inhibitors are under 
evaluation. Carfilozmib, an irreversible inhibitor of 20S chymotrypsin activity, is approved 
for the treatment of relapsed MM patients [213]. Oprozomib, ixazomib and delanzomib are 
orally bioavailable 20S inhibitors [214]. Marizomib is an orally available and irreversible 
proteasome inhibitor that blocks all three 20S proteolytic activities. Clinical trials have shown 
marizomib activity on bortezomib-resistant MM patients with no observed peripheral 
neuropathy [215].  
Another potential target for new drugs are deubiquitinases. Inhibition of proteasome cysteine 
DUBs, leads to proteasome blocking and is particularly toxic to cancer cells [216]. Our group 
recently described b-AP15, a first in class inhibitor of the proteasome DUBs, USP14 and 
UCHL5 [217]. b-AP15 and its optimized lead VLX1570 generate response characteristic for 
proteasome blocking such as induction of p21Cip1, p27Kip1 and p53, massive accumulation of 
polyubiquitin chains, strong protetoxicity of misfolded proteins and expression of molecular 
chaperons (heat shock proteins) [218].  
Interestingly several other DUB inhibitors have been described. WP1130 (degrasyn) is a 
small-molecule compound that inhibits Usp9x, USP5, USP14 and UCHL5. WP1130 induces 
the accumulation of polyubiquitin chains and reduces the level of anti-apoptotic protein 
MCL1 [219]. WP1130 has been shown to have antitumor activity in mouse xenograft models 
of prostate cancer. P5091 is a specific inhibitor of USP7, effective on bortezomib-resistant 
multiple myeloma xenografts. P5091 induces apoptosis, blocks angiogenesis, inhibits tumor 
growth and prolongs survival [220]. AC17 is a 4-arylidene curcumin analogue that 
irreversibly inhibits 19S RP DUB activity. AC17 inhibits NFκB activity and reactivates the 
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p53 tumor suppressor. It had significant inhibitory effect on in a lung carcinoma xenograft 
model with no observable toxicity [221]. 9-ethyloxyimino-9H-indeno[1,2-b]pyrazine-2,3-
dicar-bonitrile (USP8i) was shown to inhibit the activity of USP8 in non–small cell lung 
carcinoma (NSCLC). Inhibition of USP8 increased the down-regulation of oncogenic RTKs 
such as EGFR, ERBB2, ERBB3 and Met [222]. IU1 was identified as a specific inhibitor of 
USP14. Interestingly IU1 mediated inhibition of a single 19S DUB enhanced proteasomal 
degradation, shifting research interest from cancer therapeutic to neurodegenerative diseases 
associated with the accumulation of misfolded proteins [223]. Finally inhibition of ubiquitin 
receptor Rpn13 by RA-190 has been proposed as a treatment for  MM [224]. 
1.5. IMMUNOPROTEASOME 
In addition to the conventional 26S proteasomes an alternative form called the 
immunoproteasome (i-proteasome) has been identified.  Level of i-proteasome is elevated in 
cells of hematopoietic origin, whereas in other cell types i-proteasome assembly is induced 
by oxidative stress and proinflamatory cytokines such as interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α) [225]. Upon stimuli three catalytic subunits of 20S core β1, β2 and 
β5 are replaced by their homologs: iβ1/LMP2, iβ2/LMP10, and iβ5/LMP7, respectively 
[226]. The inducible counterparts have higher trypsin-like and chymotrypsin-like activities 
and lower levels of caspase-like activity, which results in preferential generation of 
oligopeptides with hydrophobic C termini [227]. 
 
Figure 4. Formation of constitutive and immunoproteasome 
Additionally, IFN-γ stimulates expression of proteasome activator 28 (PA28), which 
regulates access to the catalytic core [228]. Interestingly IFN-γ induced dephosphorylation of 
the 20S CP favors association of the catalytic core with PA28, potentially leading to 
enhanced i-proteasome activity [229]. The final cleavage products of i-proteasome substrates 
are generally 8-10 amino acid long and can be loaded onto MHC class I molecules for 
presentation to cytotoxic T cells as a part of immuno-surveillance. The distinct enzymatic 
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preferences of the i-proteasome generate more peptides with C-terminal hydrophobic anchor 
capable to interact with molecular cleft in MHC I [230]. Antigen processing is an essential 
function of i-proteasomes. Furthermore i-proteasomes have been shown to preserve cellular 
homeostasis upon oxidative stress and inflammatory damage. Finally, i-proteasomes are 
directly involved in regulation of several essential cellular pathways, such as NF-κB pathway 
components [231]. The cellular proteasome population is dynamic and contains a mixture of 
20S constitutive proteasomes and i-proteasomes, with various combinations of both standard 
and i-subunits [232]. Additionally, different variants of catalytic core may interact with 19S 
or PA28 regulatory complex forming a 20S-PA28-19S hybrid and theoretically multiple 
combinations with distinct biological functions are possible. Large diversity of produced 
peptides is crucial not only for antigen production but also for the rapid cells response to the 
stress stimuli.  
As previously mentioned, cancer cells generally display increased levels of proteasome 
activity, however the role of i-proteasomes in cancer is less characterized [233]. Down 
regulation of i-proteasomes has been observed in esophageal, renal, skin, and head and neck 
cancers, however the biological importance for cancer cells survival and tumor development 
remains unclear. On the contrary, up regulation of the i-proteasome has been reported in 
multiple myeloma, prostate cancer and lung cancer. The inhibition profiles of clinically used 
proteasome inhibitors; bortezomib and carfilzomib show similar potency towards β5 and iβ5 
[234],[235]. Additionally carfilzomib has been shown to induce cell death in lymphoma cell 
lines with knockdown of the β5 subunit suggesting that inhibition of iβ5 solely may be 
sufficient to exert anticancer effect of proteasome inhibitors [235]. This finding prompted 
intensive search for selective inhibitors of i-proteasome subunits.  The specific iβ1 inhibitor 
IPSI-001 has displayed promising therapeutic potential for multiple myeloma treatment. 
IPSI-001 leads to accumulation of ubiquitin-protein conjugates, activates caspase-mediated 
apoptosis and inhibits proliferation of multiple myeloma cells resistant to bortezomib [236]. 
However in spite of the increasing evidence the biological relevance and therapeutic potential 
of i-proteasome inhibitors needs further investigation.  
  19 
2. AIM OF THE THESIS 
The main object of this thesis is to investigate mechanism of action, binding and 
pharmacodynamics of a novel DUB inhibitor, b-AP15 as well as its optimized lead- 
VLX1570 and to define biological markers for further investigation of clinical relevance of 
VLX1570 in Acute Lymphoblastic Leukemia and Multiple Myeloma. 
Paper I: To compare the response of cancer cells to b-AP15 and bortezomib treatment  
Paper II: To study cellular uptake, metabolism and binding of b-AP15  
Paper III: To characterize the response of multiple myeloma cells to VLX1570 treatment  
Paper IV: To elucidate the mechanism of sensitivity of acute lymphoblastic leukemia cells to 
VLX1570 treatment 
Paper V: To characterize changes in proteasome subpopulations in 3D cancer models and to 
evaluate possible influence of proteasome reorganization on cells sensitivity to proteasome 
inhibitors 
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3. RESULTS AND DISCUSSION 
3.1. PAPER I: Induction Of Tumor Cell Apoptosis By A Proteasome 
Deubiquitinase Inhibitor Is Associated With Oxidative Stress 
AIM: This study is focused on defining the differences in cellular response induced by the 
deubiquitinase inhibitor b-AP15 compared with bortezomib (Velcade), a clinically used 20S 
CP inhibitor. 
RESULTS: We found that apoptotic response induced by b-AP15 is stronger and faster 
compared with bortezomib. We investigated the direct relationship between proteasome 
inhibition and cell death with a MelJuSo UbG76V-YFP, a reporter cell line constitutively 
expressing proteasome substrate with a fluorescent tag attached. Accumulation of the 
fluorescent protein after b-AP15 treatment indicated inhibition of UPS system and preceded 
cell commitment to death. Gene expression profiling revealed that, to some extent both b-
AP15 and bortezomib induce similar stress response. Several genes associated with oxidative 
stress, ER stress, heat shock and the immediate early response were strongly up-regulated by 
both drugs. Interestingly, expression of some genes was altered more potently by b-AP15, 
suggesting that both drugs act in similar yet distinct way. The HSPA6 gene, encoding 
HSP70B’ protein was found to be induced up to 1000 fold by b-AP15 and only 60 fold by 
bortezomib. The HSP70B’ protein is a stress induced chaperone involved in mediation of the 
cellular response to severe proteotoxic stress [237]. Additionally genes associated with 
oxidative stress (HMOX-1, PHOX/p67) and immediate early response (JUN, GADD34, 
GADD45A and GADD45B) were more strongly induced by b-AP15. Genes associated with 
ER stress however, were induced to similar extend by both drugs.   
To further investigate the role of ER stress in b-AP15 and bortezomib mediated apoptosis, we 
inhibited caspase-4, which is an ER stress mediator of apoptosis [238]. Chemical or siRNA 
mediated inhibition of caspase-4 resulted in the reduction of apoptosis induced by both drugs. 
Furthermore, we found that bortezomib inhibits PKR-like ER kinase (PERK), which leads to 
the inhibition of eIF2 phosphorylation. It has been shown that eIF2α activation is an 
important cell survival mechanism, reducing misfolded proteins load on ER [239]. In contrast 
b-AP15 induces phosphorylation of eIF2α, yet the apoptotic response generated by b-AP15 
was more rapid and potent in comparison to bortezomib. This indicates that an alternative 
mechanism apart from ER stress may be crucial for induction of apoptosis by 19S DUB 
inhibitors. We measured ROS induction with fluorescent ROS probe 2’7’ dichlorofluorescin 
diacetate (DCFH-HA) and induction of HMOX1 protein and we found that b-AP15 induces 
higher level of oxidative stress compared to bortezomib. Pre-treatment with anti-oxidants 
resulted in reduced levels of apoptosis for both drugs. To confirm that the effect is due to 
ROS scavenging we ensured that the anti-oxidants used in the study do not interact with the 
drugs, in order to avoid formation of inactive complexes. In addition, using the previously 
described reporter MelJuSo cell line we analyzed the relationship between proteasome 
inhibition and ROS induction. Neither ROS scavengers nor ROS inducers resulted in the 
change of accumulation pattern of UbG76V-YFP substrate, confirming that proteasome 
inhibition is due to the drug activity and not due to alterations of proteasome function 
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mediated by oxidative stress itself. 
Additionally, we found a more rapid activation of stress proteins following b-AP15 
treatment; such as phosphorylation of JNK, accumulation of c-Jun and phosphorylation of 
p38-MAPK. We confirmed the relation between JNK activation and ROS and the 
contribution of JNK mediated pathway to apoptosis. Finally we show that b-AP15 analogues, 
generating poly-ubiquitin conjugates induce oxidative stress to the similar extend that the 
parent drug, whereas less active analogues were unable to induce poly-ubiquitin conjugates 
formation and HMOX-1 expression. 
CONCLUSION: Rapid apoptotic response induced in cells by 19S DUB inhibition with b-
AP15 is mediated by ER stress and oxidative stress. 
3.2. PAPER II:  The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched In Cells 
And Elicits Rapid Commitment To Cell Death. 
AIM: In this study we focus on mechanism of action and molecular pharmacology of b-
AP15.  
RESULTS: b-AP15 compound contains two different types of reactive Michael acceptors; α,
β-unsaturated carbonyl units and an acrylamide residue. Toxicity investigation of analogues 
with substitutions at various residue sites, led to the founding that acrylamide is not required 
for the drug induced cytotoxicity, whereas reduced reactivity of α,β-unsaturated carbonyls is 
associated with lower biological activity of b-AP15. The α,β-unsaturated dienone can easily 
react with cysteine thiol groups in deubiquitinating enzymes.  
To confirm the binding ability of the drug to USP14 and UCHL5 we performed a binding 
assay with Ub-VS probe. Treatment of cells with b-AP15 reduced Ub-VS labeling of both 
USP14 and UCHL5. Consistently inhibition of proteasome system function was confirmed in 
previously described MelJuSo UbG76V-YFP reporter cell line. Surprisingly, dilution of b-AP15 
in cell extracts led to recovery of enzymatic function, suggesting that b-AP15 is a reversible 
inhibitor. We wanted to investigate if proteasome function and b-AP15 induced apoptosis can 
also be reversed. Cells exposed to low concentration of b-AP15 accumulate UbG76V-YFP, the 
proteasome substrate p21Cip1 and polyubiquitinated proteins, however after drug removal the 
levels of the reporter proteins decreased. Interestingly b-AP15 induced cell death is 
irreversible, shown by the cleavage of caspase-3 and PARP 24h after drug removal. 1h of 
exposure to b-AP15 induces similar level of toxicity as continuous exposure. In contrast 
bortezomib requires minimum 4h of exposure to commit cells to apoptosis. We believe that 
the discrepancy between reversible binding and biological potency of b-AP15 can be 
explained by the rapid uptake and cell maintenance of the drug. 1 h incubation of the drug in 
the presence of cells is sufficient to observe a massive uptake of the compound from the 
medium. Additionally, Ligand Tracer White technique shows enrichment of the radiolabeled 
[14C]b-AP15 in the cellular compartment 30 min after exposure and retention of 
approximately 50% of the compound 10 h after wash-out. These findings suggest that a 
significant number of active molecules remain in the cells after drug removal and are able to 
maintain proteasome inhibition. We confirmed that exposure of MelJuSo cells to high 
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concentration of b-AP15 leads to accumulation of polyubiquitinated proteins, detectable even 
8 h post the drug removal. Consistently with the observations in cells, injection of b-AP15 
into mice was followed by rapid clearance of the drug from plasma.  
Michael acceptors easily interact with thiol groups in cysteins. Pre-treatment with N-
ethylemaleimide reduces cellular level of b-AP15, suggesting that rapid uptake mechanism is 
thiol-dependent. Low level of a free drug in the cell after incubation indicates binding to 
intracellular macromolecules, possibly containing thiol groups. We found that b-AP15 binds 
and irreversibly inhibits thioredoxin reductase (TrxR), which regulates cellular redox 
homeostasis. As described in Paper I oxidative stress is considered a main mediator of 
apoptosis induction by b-AP15 and possibly TrxR inhibition contributes to this response. Our 
studies however, show that TrxR inhibition with auranoufin and the combination treatment 
with bortezomib and auranofin did not result in a similar degree of HMOX-1 accumulation, 
as did the treatment with b-AP15. In addition, we did not observe accumulation of 
polyubiquitinated proteins and/or UbG76V-YFP marker. Therefore, we concluded that TrxR 
inhibition has limited importance to overall drug toxicity and does not contribute to 
proteasome inhibition by b-AP15. Finally, b-AP15 did not inhibit gluthathione reductase, 
suggesting selectivity of the drug towards specific cellular cysteines, despite potentially 
reactive structure.  
CONCLUSION: In conclusion the rapid b-AP15 uptake and enrichment in cells confers high 
cytotoxicity of the drug, despite reversible binding to proteasome deubiquitinases. 
3.3. PAPER III: The Proteasome Deubiquitinase Inhibitor VLX1570 Shows 
Selectivity For Ubiquitin-Specific Protease-14 And Induces Apoptosis Of 
Multiple Myeloma Cells 
AIM: In this study we examine the binding properties and cytotoxicity of an optimized lead 
of the 19S deubiquitinase inhibitor b-AP15 (VLX1570) and its possible clinical relevance for 
multiple myeloma treatment.  
RESULTS: As described in study I and II, b-AP15 is a highly cytotoxic compound, however 
the poor solubility limits its clinical importance. An optimized lead with an improved 
solubility has been synthetized and proved to induced response similar to b-AP15 [240]. As 
b-AP15, VLX1570 contains Michael acceptor groups; therefore it is expected to bind 
cysteine residues in cellular enzymes. Using surface plasmon resonance (SPR), UB-VS probe 
labeling and Cellular Thermal Shift Assay (CETSA), we confirm binding of VLX1570 to 
USP14 and UCHL5 both in vitro and in vivo. Notably, we consistently report greater 
inhibition of USP14 in comparison to UCHL5. To confirm the relation between drug toxicity 
and DUB inhibition we performed siRNA knock-down experiment. Depletion of USP14 or 
UCHL5 resulted in decreased cell viability. The toxicity was due to the down-regulation of 
DUB activity, since VLX1570 compound and siRNA knock-down did not affect the 
proteolytic capacity of 20S proteasome. Additionally, we performed pulse and chase studies 
and as in study number II we observed retention of the drug in cells. This explains the strong 
toxicity of the compound despite reversible binding 
A compound with a similar structure to b-AP15/VLX1570 was found to block ubiquitin 
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receptor Rpn13/ADMR1 [241], [242]. We found however, using density gradient 
centrifugation, co-sedimentation of accumulated polyubiquitinated proteins together with an 
intact proteasome structure. We therefore concluded that VLX1570 does not inhibit 
recognition and binding of ubiquitin conjugates to the proteasome, suggesting that ubiquitin 
receptor remains active.  
Cytotoxicity of VLX1570 was tested on multiple myeloma cell lines and we found that the 
compound induces similar level of apoptosis to b-AP15. Cellular toxicity was determined by 
caspase-3 cleavage, accumulation of polyubiquitinated proteins, induction of chaperone 
Hsp70B’, oxidative stress marker HMOX-1 and JNK pathway activation. Development of 
new proteasome inhibitors is essential in overcoming resistance developed to clinically used 
bortezomib. We failed to establish a cell line resistant to VLX1570, despite continuous 
culture of the cells with low does of the drug, however OPM2-BzR, a multiple myeloma cell 
line selected for bortezomib resistance was partially insensitive to VLX1570 treatment. We 
investigated further the resistance mechanism of OPM2-BzR cell line. While the DUB 
inhibition was not affected, we could observe a lower level of polyubiquitinated proteins and 
decreased intake of the drug. Finally we show anti multiple myeloma activity of VLX1570 in 
vivo. Reduction in tumor volume and positive survival effect was observed in xenograft 
multiple myeloma models in mice. 
CONCLUSION: We conclude that VLX1570 is a promising candidate drug for treatment of 
bortezomib resistant multiple myeloma and is currently in Phase I trials in the USA 
(NCT02372240, clinicaltrials.gov) 
3.4. PAPER IV: Acute Lymphoblastic Leukemia Cells Are Sensitive To 
Disturbances In Protein Homeostasis Induced By Proteasome Deubiquitinase 
Inhibition 
AIM: In this paper we examine alterations in protein synthesis in acute lymphoblastic 
leukemia (ALL) cell lines in response to VLX1570 treatment.  
 
RESULTS: We determined senistivity of 9 ALL cell lines to VLX1570 and found that most 
of the cells were highly sensitive with IC50 in the range of 50-100nM. The level of 
sensitivity in these cells was similar to that of multiple myeloma cells tested in study III, 
which exepmlifies the general vulnerability of cells with high protein turn over rate to 
proteasome inhibition. As previosuly shown, treatment with VLX1570 at cytotoxic doses 
resulted in accumulation of polyubiquitinated proteins and stress markers such as HSP70B’, 
p21Cip and HMOX-1.  
Suprisingly we found that increase of the compund concentration over certain level leads to 
decrease of the markers expression. To investigate this phenomenon further, we exposed 3 
different ALL cell lines to VLX1570 and perforemd proximity antibody-based extension 
multiplex assay ProSeekTM  to examine expression of 184 protein marekrs. Amongst 70 
common markers found in all 3 ALL cell lines,  HMOX-1, p21Cip1 and VEGF-A were most 
strongly induced. Several proteins, however, decreased significantly after exposure to the 
compound. The effect was most promient for the sensitive cell lines and for high doses of 
VLX1570. Treatment with concentration 10 times higher than IC50 resulted in dimishing of 
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forementioned marker proteins. Comparison of expression between insoluble and soluble 
cell fractions did not show any differeces, therefore this discrepancy can not be simply 
explained by inclusion of the proteins into insoluble cell fraction but rather by changes in 
protein synthesis. In order to examine protein synthesis  rate we measured incorporation of 
[3H]-leucine in cells treated with VLX1570. We have observed a dose dependent decrese in 
[3H]-leucine incorporation, already at 6h after incubation, when cells viabilty was not 
affected. The repression effect was stronger in sensitive SUP-B15 cells in comparison to 
more resistant MOLT-4 cells, suggesting that decreased protein synthesis does not provide 
protection mechanims to protesome inhibition. Correlation between exposure to high 
doeses of VLX1570 and impared protein synthesis provides, however, the explanation for 
vanishing of proteins such as HMOX-1, HSP70B’ or p21Cip1. In most of the tested cell lines 
however, proteasome inhibition was not correlated to decreased protein synthesis.  
Treatment with L-asparaginase (L-asp) is an approved therapy for ALL. L-asp is known to 
affect amino acid homeostasis in ALL cells and we found that it causes a subtle but 
significant reduction of [3H]-leucine incorporation in all tested cells lines. Inhibition of 
proteasome and disturbancies in amino acid synthesis could have potentially synergistic 
effects. We combined VLX1570 with L-asp and found a strong synergistic effect between 
this two compounds  in sensitive SUP-B15 cell line and an additive effect in remaining cell 
lines. The effect of combination on protein synthesis, had however a very minor effect, 
suggetsing a distinct mechanism of protein synthesis reduction conferred by this two 
compounds.  
In order to find the mechanim behind protein synthesis repression, we examined the 
phosphorylation pattern of two markers: EIF2α- a protein translation regulator; and  
eukarotic elongation factor 2 (EF2K), involved in repression of elongation phase of protein 
synthesis. No phosphorylation of EIF2α or EF2K was observed at pharmacologically 
relevant  concentrations. In addition, combination of VLX1570 and L-asp did not lead to 
accumulation of phosphorylated  EIF2α. Finally, we investigated the effect of Integrated 
Stress Response Inhibitor (ISRIB), a small molecule known to circumvent inhibitory 
pathway of  EIF2α  phosphorylation. Treatment with ISRIB did not overcome the effect of 
VLX1570 on protein synthesis, therefore we concluded that protein synthesis  
downregulation in  ALL cells exposed to VLX1570 is uncoupled to phosphorylation of 
eIF2α.  
 
CONCLUSION: VLX1570 leads to disruption of protein homestasis in ALL cells and is a 
promising canditate for treatment of acute lymphoblastic leukemia, as a single therapy 
agent or with combination with  clinically used L-asp. 
3.5. PAPER V:  Induction Of PA28 In 3D Culture Confers Resistance To 
Proteasome Inhibitors 
 
AIM: In this study we suggest upregulation of immunoproteasome as the possible 
mechanims of resistance to proteasome inhibitors in solid tumors. 
 
RESULTS: We have investigated the effect of proteasome inhibitors on multicellular 
spheroids (MCS) and found that effectiveness of the treatment is decreased along the 
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diameter of spheroid. Exposure to bortezomib or b-AP15 induced response typical for 
proteasome inhibitors (induction of p53, p21Cip1 and caspase 3) in the periphery of MCS, 
while the inner parts remained unaffected. In order to explain the mechanim behind this 
resistance we analysed expression pattern of proteasome subunits on a panel of cell lines 
cultured as MCS. We have obsereved strong up regulation of PSME1 and PSME2 proteins, 
the components of PA28 regulatory particle. Notheworthy this effect was significantly 
lower in immortalised retinal epithelial cells cultured as MCS, suggesting the response 
pathway typical for cancer cells. With RT-PCR analysis we have confirmed  that induction 
of PSME1 occurred on the transcriptional level, with 10-fold induction after 7 days of 
growth in3D culture, while expression of 20S or i20S was less affected. 
Immunochistochemistry staining of MCS sections revealed that indcution of 
PSME1/PSME2 occurred mainly in the spheroid core, whereas PSMB5, a 20S subunit,  
was localised primary in the periphery. This observation suggested that previously observed 
resistance of MCS core to proteasome inhibitors could be partially explained by 
upregulation of PA28 proteasome subunit. Treatment with proteasome inhibitors of 
HCT116 cell lines stably overexpressing PSME1 or PSME2 confirmed that apoptotic 
response was decreased in those cells in comparison with HCT116 wild type. Staining of 
tumor biopsies from mouse model of lewis lung carcinoma showed increased level of 
PSME1. Interestingly  tumors from b-AP15 treated animals show up regulation of PSME1 
in areas unaffected by the treatment. Since i-proteasome is known to be induced under  
oxidative stress or inflammation we were interested if similar response can occur upon 
exposure to other stress condition. Solid tumors tend to have regions with poor vasculature 
which are subjected to low pH, therefore we investigated the expression pattern of PSME 
upon exposure to low pH. Transient exposure as well as adaptation to low pH lead to 
increased expression of PA28 particles. mRNA sequencing revealed that under conditions 
of low pH, induction of PA28 was correlated with reduced levels of PSMD14, a 
constitutive 19S DUB. Interstingly proteolytic activity of i-20S components were found 
lower in both cells cultured in low pH and in 3D, suggesting distinct mechanism between 
induction of PA28 regulatory particle and 20S catalytic core.  
 
CONCLUSION: Induction of PA28 observed in multicellular spheroid model can partially 
explain the resistance mechanims to proteasome inhibitors in solid tumors.
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4. CONCLUSIONS AND FUTURE PERSPECTIVES 
4.1. b-AP15 is a reversible inhibitor with an irreversible activity 
b-AP15 contains two Michael acceptors, which interact easily with nucleophiles such as thiol 
groups. We have concluded that Michael reaction occurs between b-AP15 α,β-unsaturated 
carbonyl units and the cysteine located at the enzymatic catalytic triad of USP14/UCHL5. 
Interestingly, we did not observe a general inhibition of cytoplasmic DUBs suggesting a 
degree of specificity. In addition molecules that share structural features with b-AP15 such as 
WP1130 or AC17 seem to inhibit a different set of DUBs, suggesting specificity of 
interaction between these molecules and their primary targets [219],[221]. We have found 
that inhibition of USP14/UCHL5 with b-AP15 is reversible, both in vitro and in cellular 
assays, however commitment to death induced by the drug is irreversible. We believe that 
this phenomenon can be explained by the fast uptake of the drug and its subsequent retention 
in the cellular compartments. We have observed rapid clearance of b-AP15/VLX1570 from 
cell incubation media and in animal tumor models; VLX1570 disappeared from plasma 
shortly after the treatment. Such fast distribution can be clinically beneficial, as short 
exposure to the drug will result in prolonged effect.  
4.2. b-AP15/ VLX1570 toxicity is due to 19S DUB inhibition  
Our group has previously shown that b-AP15 inhibits the two 19S DUBs, USP14 and 
UCHL5. VLX1570 is an analogue of b-AP15 with a strong anticancer activity and increased 
solubility, optimized for clinical application. By multiple in vitro and cellular assays 
(enzymatic assays, reporter cell line, Ub-VS labeling, SPR, CETSA) we have confirmed 
binding of VLX1570 to USP14/UCHL5, with stronger affinity towards USP14. siRNA 
mediated knockout of USP14 or UCHL5 resulted in reduced viability of multiple myeloma 
cells, known to have high expression level of USP14. VLX1570/b-AP15 is an inhibitor of 
USP14/UCHL5, whereas bortezomib and other clinically available inhibitors block the 
activity of the 20S catalytic core. Different mechanism of action gave the possibility to use 
DUB inhibitors for relapsed and refractory multiple myeloma resistant to conventional 
proteasome inhibitors. 
4.3. b-AP15 and bortezomib elicit similar yet distinct cellular response 
As discussed previously b-AP15 and bortezomib interfere with proteasomal degradation, 
however the cellular response to 19S DUB inhibition is different to the one induced by 
bortezomib. Although treatment with bortezomib as well as with b-AP15 results in the 
accumulation of proteasome substrates (p53, p21Cip, p27Kip1), apoptotic response induced by 
b-AP15 is stronger and more rapid. In addition treatment with b-AP15 induces more potent 
proteotoxic response (indicated by massive accumulation of chaperone HSP70B’) and higher 
levels of ROS. This data taken together suggests distinct mechanisms behind b-AP15 and 
bortezomib mediated cytotoxicity. One possible explanation to the discrepancy between the 
two drugs is that the inhibition of DUBs leads to accumulation of misfolded proteins with 
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longer polyubiquitin chains than inhibition of 20S proteolytic core. Massive accumulation of 
polyubiquitinated proteins may disrupt the integrity of cellular membranes and organelles and 
indeed treatment with VLX1570 (b-AP15 homolog) was found to increase permeability of 
mitochondria outer membrane [243].  
 
Figure 5 Mechanism of proteasome inhibition induced by bortezomib and b-AP15 
Increased permeability of mitochondrial membrane may contribute to high levels of toxic 
ROS and we found ROS induction to be crucial for b-AP15 mediated toxicity. On the other 
hand we have synthetized a group of b-AP15 analogues for which induction of HMOX-1 was 
not correlated with apoptosis or accumulation of polyubiquitin chains. Finally, the differences 
in cellular response to these two compounds may be attributed to off-targets of the drug. We 
identified TrxR as one of b-AP15 off-targets and although TrxR inhibition contributed only 
mildly to overall drug toxicity it cannot be excluded that other, not yet identified targets 
enhance the potency of b-AP15.  
4.4. ER stress is not essential for VLX1570 mediated toxicity in ALL cells 
Cancer cells of hematopoetic origin such as MM are known to be sensitive to proteasome 
inhibition [243],[244]. Consistently we have discovered similar level of sensitivity to 
VLX1570 in ALL cells. Induction of ER stress (detected as phosphorylation of EIF2α) is 
consider as a typical response to proteasome inhibition and is associated with massive 
accumulation of misfolded polyubiquitinated proteins [149],[217]. In ALL cells we observed 
accumulation of poly-Ub chains in a dose dependent manner, however this was not related to 
ER stress. Furthermore the pattern of EIF2α phosphorylation did not correlate with drug 
induced cytotoxicity. Inhibition of protein synthesis is a cellular response to many stress 
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factors and EIF2α phosphorylation is an important checkpoint mediating this pathway [245].  
Inhibition of protein synthesis is considered as a protective mechanism to proteotoxic stress 
induced by proteasome inhibitors. Surprisingly in ALL cells general protein synthesis 
inhibition did not correlate with cell sensitivity to drug treatment. This study shows how 
careful selection of relevant drug concentrations for pre clinical evaluation is crucial. In 
addition many assumptions considered dogmatic need evaluation when testing under new 
conditions.  
4.5. PA28 may alter solid tumors response to proteasome inhibitors 
Despite constantly growing interest in the field of UPS, clinical application of proteasome 
inhibitors is limited to several hematological malignancies and even though patients respond 
positively to treatment, they often acquire resistance and experience disease relapse. 
Furthermore, clinical trails performed on solid tumors were relatively unsuccessful despite 
several studies showing promising preclinical results [141]. It suggests that primary and 
acquired resistance need to be considered when new treatment based on proteasome 
inhibition is developed. 3D cultures of cancer cells mimic conditions of solid tumors growth; 
therefore we investigated the response of cells cultured as MSCs to proteasome inhibition. 
We found that layers of cells do not respond in the same way to the drug exposure and that 
outer layers are more sensitive that the spheroid core, which in fact resembles 
microenvironment of solid tumors more accurately [246]. Our preliminary results suggest 
correlation between the resistance to proteasome inhibitors and overexpression of PA28, a 
stress-induced regulatory particle of the 20S proteasome.  
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